Malignant Neoplastic Disease clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
Evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
Orange, California and other locations